Antibody response and intra‐host viral evolution after plasma therapy in COVID‐19 patients pre‐exposed or not to B‐cell‐depleting agents

Administration of plasma therapy may contribute to viral control and survival of COVID‐19 patients receiving B‐cell‐depleting agents that impair humoral immunity. However, little is known on the impact of anti‐CD20 pre‐exposition on the kinetics of SARS‐CoV‐2‐specific antibodies. Here, we evaluated...

Descripción completa

Detalles Bibliográficos
Autores principales: Gachoud, David, Pillonel, Trestan, Tsilimidos, Gerasimos, Battolla, Dunia, Dumas, Dominique, Opota, Onya, Fontana, Stefano, Vollenweider, Peter, Manuel, Oriol, Greub, Gilbert, Bertelli, Claire, Rufer, Nathalie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539045/
https://www.ncbi.nlm.nih.gov/pubmed/36101920
http://dx.doi.org/10.1111/bjh.18450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539045/
https://www.ncbi.nlm.nih.gov/pubmed/36101920
http://dx.doi.org/10.1111/bjh.18450

Ejemplares similares